Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 2, 2003. The report details specific share re-purchase activities executed in accordance with authority granted by shareholders at the Annual General Meeting on May 19, 2003.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on capital allocation via share buybacks.
| Date | Shares Purchased | Price per Share | Total Value (Approx.) |
|---|---|---|---|
| May 30, 2003 | 1,220,000 | 1,229.25p | £15,000,000 |
| June 2, 2003 | 1,200,000 | 1,218.54p | £14,622,480 |
Material Changes
The filing reports the cancellation of 2,420,000 ordinary shares in total during the reporting period. No other material changes to operations or financial position are disclosed in this specific document.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future performance, risk factors, or contingencies. The text is limited to the announcement of completed share transactions.
Investor Verification Checklist
- Verify the total number of shares authorized for repurchase at the May 19, 2003 Annual General Meeting to assess remaining buyback capacity.
- Confirm the exact total cost of the repurchases against the company's cash position in the most recent full financial report.
- Check subsequent filings for any additional share repurchases made after June 2, 2003.